Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database

多发性骨髓瘤 移植 医学 肿瘤科 硼替佐米 自体干细胞移植 养生 维持疗法 内科学 环磷酰胺 队列 外科 化疗
作者
Christopher Paul Venner,Peter Raymond Duggan,Kevin Song,Donna Ellen Reece,Smriti Sharma,Jiandong Su,Victor Hugo Jimenez-Zepeda,Arleigh B. Robertson McCurdy,Martha Louzada,Hira S. Mian,Michaël Sébag,Darrell J. White,Julie Stakiw,Rami R. Kotb,Muhammad Aslam,Tony Reiman,Engin Gul,Michael Patvin Chu,Debra J. Bergstrom,Richard LeBlanc
出处
期刊:Biology of Blood and Marrow Transplantation [Elsevier BV]
卷期号:30 (9): 889-901 被引量:9
标识
DOI:10.1016/j.jtct.2024.06.030
摘要

In patients with multiple myeloma (MM), the presence of high-risk cytogenetic abnormalities is associated with worse disease control and survival. Autologous stem cell transplant (ASCT) does benefit these patients. Tandem transplantation has been explored as a means to deepen responses and further improve survival however, its role remains controversial. This is particularly true in the era of novel agent induction and post-transplant maintenance therapy. The aim of this study was to use the Canadian Myeloma Research Group database and examine a large cohort of real-world patients comparing the outcomes of tandem versus single ASCT specifically in high-risk patients receiving novel agent-based induction and post-transplant maintenance. The data for this study was derived retrospectively from a comprehensive national-level database of Canadian patients with MM. High-risk cytogenetics was defined as presence of del17p, t(4;14), or t(14;16). Those receiving allogeneic transplant were excluded. Tandem transplantation was defined as a second ASCT performed consecutively without interim relapse or progression after first ASCT. Those with relapse or progressive disease within 3 months of completing a first transplant were excluded. We compared response depth, progression-free, and overall survival (OS) based on single or tandem transplantation procedures. The impact of covariates of interest was also assessed. A total of 381 patients with high-risk cytogenetics were identified. A total of 242 received single and 139 patients received tandem transplants. All received post-transplant maintenance. The most common induction regimen for these patients was cyclophosphamide, bortezomib, and steroids (CyBorD, 87%). Forty-one patients (10.8%) required reinduction prior to first ASCT. The best overall responses at any time were 98.3% (90.5% ≥ very good partial response [VGPR]) and 98.6% (89.9% ≥ VGPR) in the single and tandem ASCT groups, respectively. Survival outcomes were similar with the median progression-free survival for single or tandem ASCT of 35.2 and 35.3 months (P = .88) and the median OS were 92.6 and 88.9 months, respectively (P = .72). No statistically significant differences were seen based on type of cytogenetic abnormality or type of maintenance. This was confirmed on multivariate analysis. In the real-world setting, tandem ASCT does not improve outcomes for MM patients with high-risk cytogenetics. This may be driven by the use of effective pre- and post-ASCT therapies. The development of more potent induction and consolidation along with current nearly ubiquitous continuous maintenance therapies until disease progression does not support the use of a second high-dose procedure.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
wangxx发布了新的文献求助30
1秒前
1秒前
1秒前
zzyy完成签到,获得积分10
2秒前
Akim的应助被Zx采纳,获得10
3秒前
木头发布了新的文献求助10
3秒前
CodeCraft的应助被木夫贝采纳,获得10
3秒前
香蕉觅云的应助被阿冲采纳,获得10
3秒前
4秒前
失眠小懒虫完成签到,获得积分10
4秒前
打打的应助被shiv采纳,获得50
4秒前
5秒前
XPR发布了新的文献求助10
5秒前
5秒前
希望天下0贩的0的应助被精一采纳,获得10
6秒前
yize完成签到,获得积分10
8秒前
所所的应助被体贴的小馒头采纳,获得10
9秒前
刘亦然完成签到 ,获得积分10
9秒前
小马甲的应助被明前易拉罐采纳,获得10
9秒前
10秒前
川一发布了新的文献求助10
10秒前
我是老大的应助被coco采纳,获得10
11秒前
可爱的函函的应助被yize采纳,获得10
12秒前
科勒的黑猩猩完成签到 ,获得积分10
13秒前
所所的应助被栗子砸采纳,获得10
13秒前
efficient发布了新的文献求助10
14秒前
14秒前
xiaobuding完成签到,获得积分10
15秒前
丘比特的应助被路小雨采纳,获得10
15秒前
16秒前
云起完成签到 ,获得积分10
16秒前
耍酷巨人完成签到,获得积分10
16秒前
17秒前
诚心面包发布了新的文献求助10
18秒前
18秒前
哈哈哈发布了新的文献求助20
18秒前
19秒前
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621